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Abstract 
Adoptive cell therapy can be an effective treatment for some patients with advanced 
cancer.  This report summarizes clinical trial results from the Surgery Branch, NCI, in-
vestigating tumor infiltrating lymphocytes (TIL) and gene engineered peripheral blood T 
cells for the therapy of patients with melanoma and other solid tumors. 
Key words: TIL, melanoma, NY-ESO-1, interleukin-2, lymphodepletion 
Adoptive  T  cell  therapy  (ACT)  consists  of  iso-
lating  tumor  reactive  lymphocytes  from  a  patient, 
growing and activating them in the laboratory, and 
infusing  them  back  into  the  autologous  patient  [1].  
ACT can be an effective treatment for patients with 
refractory melanoma, and potentially other advanced 
cancers.  Clinical trials in the Surgery Branch of the 
National Cancer Institute have focused on two aspects 
of ACT.  First, the role of lymphodepletion is being 
studied,  including  its  impact  on  persistence  of  the 
infused lymphocytes and improving clinical outcome.  
Second, the role of antigen specificity is being inves-
tigated by engineering lymphocytes to express new T 
cell receptors targeting them to tumors, increasing the 
pool of patients eligible for this therapy [2].   
Several  mechanisms  have  been  identified  in 
mouse  models  for  how  lymphodepletion  improves 
antitumor  efficacy  in  ACT  [3].    These  mechanisms 
include  the  elimination  of  cytokine  “sinks”  and  ac-
cumulation  of  high  levels  of  homeostatic  cytokines 
like IL-7 and IL-15; elimination of CD4+CD25+ regu-
latory T cells that inhibit anti-tumor responses; acti-
vation of antigen presenting cells; and stimulation of 
lymphocytes  by  the  transfer  of  hematopoietic  pro-
genitor  cells.    Which  of  these  mechanisms  are  im-
portant for optimal cancer immunotherapy in human 
patients  is  not  known.    To  investigate  an  optimal 
lymphodepleting regimen for ACT in patients, three 
sequential clinical trials were undertaken [4-6].  Pa-
tients were selected for these trials who had metastatic 
melanoma  (many  refractory  to  standard  therapies) 
and  who  had  a  tumor-reactive,  tumor  infiltrating 
lymphocyte  (TIL)  culture  available  for  treatment.   
After TIL transfer all patients received high dose in-
terleukin(IL)-2  therapy  consisting  of  720,000  IU/kg 
three times per day to tolerance.  An initial cohort of 
43  patients  received  a  non-myeloablative  (NMA) 
lymphodepleting regimen consisting of two days of 
60mg/kg  cyclophosphamide  followed  by  25mg/m2 
fludarabine.  A second cohort of 25 patients received 
the same doses of NMA chemotherapy with the addi-
tion  of  2Gy  total  body  irradiation  (TBI),  and  these 
patients also received CD34+ hematopoietic stem cells 
(>2 million/kg) the day following TIL administration. 
A third cohort of 25 patients received the same doses 
of NMA chemotherapy with 12Gy TBI, and these pa-
tients also received CD34+ stem cells.  The toxicities 
due to the lymphodepletion and high dose IL-2 were 
substantial but generally transient.  One patient in the 
2Gy cohort died from sepsis due to a pre-existing but 
unappreciated diverticular abscess. Five patients en-
rolled in the 12Gy TBI group developed elevated cre-
atinine  levels  that  stabilized  or  returned  to  normal 
without  intervention.    Toxicities  due  to  TIL  admin-
istration were rare and generally minor.  Occasional 
patients had skin depigmentation or mild uveitis.   
Ivyspring  
International Publisher   Journal of Cancer 2011, 2 
 
http://www.jcancer.org 
361 
The objective clinical response rates (RECIST) in 
the NMA, 2Gy, and 12Gy cohorts were 49%, 52%, and 
72%, and the complete response (CR) rates were 12%, 
20%,  and  40%  [7].    Overall,  20  of  the  93  patients 
treated  with  lymphodepletion  plus  TIL  and  IL-2 
achieved a complete tumor regression.  Nineteen of 
the 20 are ongoing with a minimum follow up time 
over  three  years.      Regression  of  melanoma  lesions 
was seen at all sites, including brain, and some re-
sponses were very rapid.  The likelihood of response 
was not related to prior treatments or bulk of disease.  
The results from this remarkable group of patients are 
encouraging because few treatments for solid tumors 
result in durable complete responses, and the ability 
of ACT to mediate “cures” in these refractory meta-
static  melanoma  patients  suggests  that  this  therapy 
should be investigated further. 
Retrospective  analysis  revealed  several  corre-
lates  of  treatment  and  response  in  this  combined 
group of 93 patients.  All patients exhibited elevated 
circulating levels  of IL15 prior to TIL transfer, sug-
gesting  that  the  lymphodepletion  may  be  acting 
through this mechanism to enhance anti-tumor func-
tion.  T cell attributes associated with differentiation 
and  proliferative  potential,  including  CD27  expres-
sion  and  telomere  length,  also  correlated  with  re-
sponse.  These observations motivated us to develop a 
simpler,  more  reliable  methods  of  TIL  production, 
termed “young” TIL[8].  Investigators at other insti-
tutions have also adopted simplified and reliable TIL 
production  methods  and  have  reported  clinical  re-
sponses  in  patients  treated  with  this  approach[9].   
New  research  directions  with  TIL  may  include  im-
proved methods for TIL expansion, or combinations 
of ACT with ipilimumab, a BRAF inhibitor, IL-15, or 
another therapy. 
ACT  with  TIL  can  be  an  effective  therapy  for 
some  patients,  but  this  approach  is  also  logistically 
difficult and requires a surgical resection for each pa-
tient to access the endogenous T cell receptor (TCR) 
repertoire found in TIL.   TCR gene engineering al-
lows the production  of tumor reactive lymphocytes 
for  any  patient  from  peripheral  blood  lymphocytes 
(PBL) [10].  The Surgery Branch has investigated sev-
eral TCRs for retargeting PBL.  A clinical trial recently 
reported  by  Robbins  et  al  targeting  the  NY-ESO-1 
antigen demonstrates some interesting features of this 
approach [11].   The NY-ESO-1 cancer/testes antigen 
is  not  expressed  in  normal  adult  tissues  except  the 
testes, which have no class I HLA expression so are 
not a T cell target.  NY-ESO-1 is expressed by 10-50% 
of tumors of multiple histologies including melano-
ma, breast, prostate, thyroid, and ovarian.  It is also 
expressed by about 80-90% of synovial cell sarcomas.  
An  NY-ESO-1  TCR  that  is  HLA-A2  restricted  was 
optimized for antigen binding, cloned into a retrovi-
rus, and produced under GMP conditions for a clini-
cal trial. 
Eleven  patients  with  refractory  melanoma  re-
ceived  peripheral  blood  lymphocytes  (PBL)  trans-
duced to express the ESO TCR following NMA lym-
phodepletion with IL-2.  Five patients had an objec-
tive  response  (RECIST)  including  two  complete  re-
sponses.  Additionally, 6 patients with synovial cell 
sarcoma were treated with ESO TCR transduced PBL 
following  NMA  lymphodepletion  with  IL-2.      Four 
patients responded to therapy.  Toxicities due to the 
cells were minimal.  These results demonstrate that 
solid  tumors  other  than  melanoma  can  respond  to 
ACT when tumor reactive lymphocytes are adminis-
tered in appropriately conditioned patients.  Further 
clinical trials with NY-ESO-1 aimed at improving the 
response rate, extending the durability of responses, 
and increasing patient accrual to protocols are ongo-
ing.    Other  antigens  are  expressed  on  tumors  and 
susceptible  to  attack  by  retargeted  lymphocytes  in-
cluding MAGE-A3 on tumors of multiple histologies, 
and CD19on lymphomas and leukemias.   
These  studies  demonstrate  that  ACT  can  be  a 
potent and effective therapy for patients with refrac-
tory  melanoma.    TIL  therapy  for  melanoma  can  be 
widely applied, and studying the correlates of treat-
ment and response allow us to improve next genera-
tion therapies.  TCR gene engineering simplifies the 
manufacturing  of  the  individual  patient  treatments 
and extends ACT to diverse tumor histologies. 
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